• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

AZD-1480 Drug Record

  • Summary
  • Interactions
  • Claims
  • AZD-1480 chembl:CHEMBL1231124 Antineoplastic

    Alternate Names:

    AZD1480
    AZD-1480
    AZD 1480

    Drug Info:

    Drug Class Kinase Inhibitors
    (2 More Sources)

    Publications:

    Deshpande et al., 2012, Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms., Leukemia
    Ioannidis et al., 2011, Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway., J. Med. Chem.
    Hou S et al., 2014, Novel carbazole inhibits phospho-STAT3 through induction of protein-tyrosine phosphatase PTPN6., J Med Chem
    Couto et al., 2012, AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines., PLoS ONE
  • AZD-1480   STAT5A

    Interaction Score: 12.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21138246


    Sources:
    DTC

  • AZD-1480   STAT3

    Interaction Score: 1.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21138246 24978112


    Sources:
    DTC

  • AZD-1480   JAK2

    Interaction Score: 1.0

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Response Type resistant

    PMIDs:
    21926964


    Sources:
    MyCancerGenome JAX-CKB ChemblInteractions TTD

  • AZD-1480   JAK1

    Interaction Score: 0.62

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • AZD-1480   RET

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type thyroid medullary carcinoma
    Response Type sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    23056499


    Sources:
    JAX-CKB

  • MyCancerGenome: AZD1480

    • Version: 20-Jun-2017

    Alternate Names:
    AZD1480 Development Name

    Drug Info:
    Drug Class Kinase Inhibitors

    Publications:

  • DTC: AZD-1480

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1231124 ChEMBL Drug ID

    Drug Info:

    Publications:
    Ioannidis et al., 2011, Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway., J. Med. Chem.
    Hou S et al., 2014, Novel carbazole inhibits phospho-STAT3 through induction of protein-tyrosine phosphatase PTPN6., J Med Chem

  • JAX-CKB: AZD1480

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Deshpande et al., 2012, Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms., Leukemia
    Couto et al., 2012, AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines., PLoS ONE

  • TTD: AZD1480

    • Version: 2020.06.01

    Alternate Names:
    D0MP0X TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1231124

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1231124

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21